P9 Biomarker Panel to Predict Hepatocellular Cancer Risk in Cirrhosis Patients

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-02-27T17:30:39+05:30 | Updated On 27 Feb 2024 5:30 PM IST

A recent study published in the BMJ Gut unveiled a novel biomarker panel that could revolutionize the prediction of hepatocellular cancer (HCC) risk in patients with cirrhosis. This research was conducted as a part of a longitudinal phase III study explores the intricate relationship between inflammatory and metabolic biomarkers and the onset of HCC.

This study led by a team of Hashem El-Serag utilized data from a prospective cohort of 2266 adult patients with cirrhosis, who were meticulously monitored until the emergence of HCC. Through a meticulous process, the study custom-designed a FirePlex immunoassay to gauge baseline serum levels of 39 biomarkers by ultimately identifying a set of nine biomarkers with the highest discriminatory ability for HCC.

These nine biomarkers was collectively termed as P9 included insulin growth factor-1, interleukin-10, transforming growth factor β1, adipsin, fetuin-A, interleukin-1 β, macrophage stimulating protein α chain, serum amyloid A, and TNF-α. When integrated into existing clinical models, P9 expressed a promising predictive performance.

The addition of P9 to established clinical models, like the AFP (alpha-fetoprotein) model and aMAP score resulted in substantial improvements in the prediction of HCC risk. When combined with the AFP model, the incorporation of P9 boosted the area under the receiver operating characteristic curve (AUROC) by 4.8% and 2.7% at 1 and 2 years, respectively. Also, when added to the aMAP score, P9 enhanced AUROC by 14.2% and 7.6% at 1 and 2 years, respectively. The potential to refine risk stratification models for HCC offers clinicians a more precise tool to identify patients who are at heightened risk.

Reference:

El-Serag, H., Kanwal, F., Ning, J., Powell, H., Khaderi, S., Singal, A. G., Asrani, S., Marrero, J. A., Amos, C. I., Thrift, A. P., Luster, M., Alsarraj, A., Olivares, L., Skapura, D., Deng, J., Salem, E., Najjar, O., Yu, X., Duong, H., … Kaochar, S. (2024). Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. In Gut (p. gutjnl-2024-332034). BMJ. https://doi.org/10.1136/gutjnl-2024-332034

BMJ Guthepatocellular cancerCirrhosis patients

Source : BMJ Gut

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751